The way medicines are discovered is being completely reinvented by AI, and it's happening right now. The companies in this group are at the very centre of that change, and early movers in transformative industries have historically been worth paying close attention to.
When a company like Novo Nordisk partners with OpenAI, the rest of the industry takes notice — and follows. This basket gives you exposure to the global pharma titans and AI powerhouses driving this wave, not just the ones watching from the sidelines.
This group uniquely spans both the healthcare and technology industries, two of the most closely watched investment spaces today. That means you could potentially benefit from growth on both sides of this fast-moving partnership.
This basket's total market capitalisation is 1,554,559.72609 and is dominated by a few very large-cap constituents, producing a large-cap-weighted, relatively stable profile. Smaller names hold a much smaller share, so overall performance will generally track the large-cap movers rather than idiosyncratic small-cap swings.
LLY: $871.60B
PFE: $154.21B
BIIB: $26.26B
Novo Nordisk's landmark partnership with OpenAI has sparked a broader shift across the entire pharmaceutical industry. Major drugmakers are now racing to embed generative AI into their core operations, from discovering new medicines to running clinical trials more efficiently. This basket is built around that transformation, capturing both the pharma companies modernising their pipelines and the tech firms powering the AI infrastructure behind it all.
This group spans two distinct but connected worlds: pharmaceutical and biotech companies using AI to reduce costs and improve drug success rates, and technology companies providing the cloud, data, and computing infrastructure that makes it all possible. This diversity means exposure to both healthcare innovation and the growing enterprise AI market, though as with any growth-focused group, some individual stocks may carry higher risk than others.
Every stock in this group was handpicked by professional analysts in direct response to the high-profile Novo Nordisk and OpenAI collaboration. The selection includes biotech innovators using AI as their core engine, global drugmakers integrating AI into deep pipelines, and specialised tech providers supplying the foundational infrastructure. These are not random picks — they represent a carefully curated view of who stands to benefit most from healthcare's computational future.
Novo Nordisk's partnership with OpenAI highlights a massive shift as major drugmakers integrate generative AI into their core operations. This basket captures the pharmaceutical giants optimizing their pipelines alongside the tech titans providing the underlying AI infrastructure.
Veröffentlicht am April 15
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly & Co
LLY
Aktueller Kurs
$1,294.29
Eli Lilly is a leading pharmaceutical titan aggressively adopting generative AI and digital health platforms to accelerate its drug discovery and comm...
Eli Lilly is a leading pharmaceutical titan aggressively adopting generative AI and digital health platforms to accelerate its drug discovery and commercialisation efforts.
BIOGEN INC
BIIB
Aktueller Kurs
$245.78
Biogen is a major biopharmaceutical company increasingly utilising data and advanced technologies to accelerate its pipeline for serious neurological ...
Biogen is a major biopharmaceutical company increasingly utilising data and advanced technologies to accelerate its pipeline for serious neurological diseases.
Join Nemo FREE today and unlock every stock
Es dauert nur 60 Sekunden.
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Vollständige Analyse lesen
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 179.58 % zulegen.
11 von 14 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+179.58%
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
